Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention

Gilead Sciences (GILD) received FDA approval for Yeztugo (lenacapavir), a twice-yearly injectable HIV-1 capsid inhibitor for PrEP, marking the first and only option of its kind in the U.S. for adults and adolescents; analysts, including BMO Capital (Outperform, $120 PT), view the approval as a significant growth driver for Gilead's PrEP business, citing strong clinical data and a clean label facilitating physician adoption; additionally, Gilead reported positive data from the ASCENT-04 trial for Trodelvy in combination with Keytruda for triple-negative breast cancer, while also developing a once-yearly lenacapavir formulation for PrEP, expected to enter Phase 3 trials in the second half of 2025.

Analysis

Gilead Sciences, a biotechnology firm with $28.7 billion in annual revenue and a 78% gross profit margin, has secured a significant regulatory milestone with the FDA approval of Yeztugo (lenacapavir), its twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP). This approval establishes Yeztugo as the first and only such option in the United States for adults and adolescents, a development viewed by analysts, including BMO Capital which reiterated an Outperform rating and a $120 price target, as a pivotal driver for meaningful growth within Gilead's PrEP franchise. The optimism is supported by strong clinical data from the PURPOSE-1 and PURPOSE-2 trials and a clean label expected to facilitate physician adoption. The long-acting nature of Yeztugo, offering a substantial improvement in dosing convenience over daily oral options, is anticipated to enhance patient adherence and potentially expand the overall PrEP market. Analyst sentiment for the $134 billion market cap company is broadly positive, with price targets generally ranging from $93 to $140; Morgan Stanley projects Yeztugo sales reaching $184 million in 2025 and $760 million by 2026. Further bolstering Gilead's outlook, the company reported promising Phase 3 data for Trodelvy in combination with Keytruda for triple-negative breast cancer, showing a 35% reduction in disease progression or death risk, and is advancing a once-yearly formulation of lenacapavir for PrEP into Phase 3 trials in late 2025. Despite these positive developments and strong analyst backing, InvestingPro’s Fair Value analysis indicates Gilead is currently fairly valued.

Key Decisions for Investors

• Investors should assess Gilead's near-term performance based on Yeztugo's market penetration and revenue contribution, which are critical to realizing the projected growth in the PrEP segment.
• The progression of Gilead's oncology pipeline, especially Trodelvy, and the development of the once-yearly lenacapavir PrEP formulation should be monitored as key indicators of future growth diversification and market expansion.
• While analyst sentiment is strongly positive with upward price target revisions, investors should weigh the 'fairly valued' assessment against the significant growth catalysts to determine appropriate entry or adjustment points for GILD positions.